All In Biotech

Drug Trial Radar · NCT02791334

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

164

Actual

Start

Jun 29, 2016

Primary completion

May 22, 2020

Study completion Jun 27, 2024

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Conditions

  • Solid Tumor
  • Microsatellite Instability-High (MSI-H) Solid Tumors
  • Cutaneous Melanoma
  • Pancreatic Cancer
  • Breast Cancer (HR+HER2-)

Interventions

  • LY3300054Drug

    Administered IV

  • RamucirumabDrug

    Administered IV

  • AbemaciclibDrug

    Administered orally

  • MerestinibDrug

    Administered orally

  • LY3321367Drug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs)Time frame: Baseline through Cycle 1 (Approximately 28 Days)

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • The START Center for Cancer Care

    San Antonio, Texas

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, France

  • Gustave Roussy

    Villejuif, France

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Madrid Norte Sanchinarro

    Madrid, Spain

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.